Vertex Pharmaceuticals Incorporated

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 2026

Phase 3 RAINIER interim results for povetacicept in IgA nephropathy were published in NEJM and presented at ASN Kidney Week 2026, showing a 52.0% reduction from baseline in proteinuria at Week 36 and a 49.8% reduction versus placebo (P<0.0001), with both secondary endpoints met. Trial results support Vertex's BLA for accelerated approval in adults with IgAN, with the FDA PDUFA target action date set for November 30, 2026. Patient-preference data showed 96% of IgAN patients preferred an autoinjector over a prefilled syringe and 80% preferred dosing every 4 weeks versus weekly, supporting Vertex's planned at-home autoinjector launch. Povetacicept is Vertex's pipeline-in-a-product asset with ongoing studies in membranous nephropathy (OLYMPUS) and generalized myasthenia gravis (ETNA).

•9d ago

Vortex Energy Receives Government Approval for Ground Gravity Survey at Robinsons River Salt Project

Vortex Energy has secured government approvals, permits, and land access to begin its planned ground gravity survey at the Robinsons River Salt Project in Newfoundland and Labrador. The survey comprises roughly 500 measurement stations over about 22 working days, targeting gaps west of the Cloverleaf target and in the eastern block, with data to be integrated against historical seismic and airborne gravity-gradiometry datasets. Results are intended to refine subsurface salt-structure interpretation and guide future exploration drilling decisions, including potential salt cavern hydrogen storage targets.

•10d ago

Vertex to Present New Data on ALYFTREK® at the North American Cystic Fibrosis Conference

Vertex presented interim data at NACFC showing ALYFTREK restored exocrine pancreatic function in some children ages 2-5, with 37.5% of the 48-child substudy successfully discontinuing pancreatic enzyme replacement therapy. Mean fecal elastase-1 rose 110.2 µg/g from baseline to 239.7 µg/g, with nearly half of children reaching the sufficiency threshold — challenging the long-held view that pancreatic failure in CF is irreversible. Use of ALYFTREK in children 2 to 5 remains investigational; the data support long-term franchise depth rather than a near-term regulatory or revenue catalyst.

•23d ago

Vortex Energy Completes Acquisition of the Meadows Project in Saskatchewan

Vortex Energy Corp. has completed its acquisition of the Meadows Project in west-central Saskatchewan, near the Alberta border, under Saskatchewan Subsurface Mineral Permit #SMP273. The deal, originally announced September 17, 2026, gives Vortex 100% of Global Strategic Minerals Corp.'s interest in the permit, plus transferable technical information and governmental authorizations. Vortex remains an exploration-stage company also advancing the Robinson River Salt Project in Newfoundland & Labrador and the Fire Eye Uranium Property in the Athabasca Basin.

•1mo ago

Vertex Announces Positive Results From Phase 2b AMPLIFIED Study of Inaxaplin in Additional Populations of People With APOL1-Mediated Kidney Disease (AMKD) and Completion of Enrollment in the Phase 2/3 AMPLITUDE Trial

Vertex reported positive Phase 2b AMPLIFIED results for inaxaplin in APOL1-mediated kidney disease, with a -42.7% reduction in urine albumin-to-creatinine ratio at Week 13 in the modest-proteinuria cohort and a -17.3% reduction in the type 2 diabetes cohort. Results in the modest-proteinuria cohort were consistent with the prior Phase 2a FSGS study, and inaxaplin was generally safe and well tolerated with no related serious adverse events. Vertex has completed enrollment in the pivotal Phase 2/3 AMPLITUDE trial and remains on track for an interim analysis in early 2027, which if positive could support potential accelerated approval in the U.S. There are currently no approved therapies for AMKD, which affects approximately 150,000 people in the U.S. and Europe, making inaxaplin a potentially first- and best-in-class opportunity for Vertex.

•1mo ago

Vortex Energy Enters Into Asset Purchase Agreement to Acquire the Meadows Project in Saskatchewan

Vortex Energy Corp. has signed an asset purchase agreement to acquire 100% of the Meadows Project in west-central Saskatchewan from Global Strategic Minerals Corp. for C$255,000 in cash. Alongside the purchase price, Vortex assumes permit obligations including annual rentals of about $43,219 in years one through five and $108,047 in years six through eight, plus a work commitment of roughly $9.81 million over the next eight years. The project covers about 21,609 hectares across 338 Crown parcels, targeting salt in the Elk Point Group with potential applications for compressed air energy storage and hydrogen storage, though the presence, thickness and quality of the salt remain unconfirmed. Closing is expected on or about October 1, 2026, subject to regulatory and third-party approvals, and the company cautions the transaction may not complete on the contemplated terms or at all.

•1mo ago

Vertex Partners With World Champion Skier Lindsey Vonn to Raise Awareness of JOURNAVX®, a Non-Opioid Medicine Approved for the Treatment of Moderate-to-Severe Acute Pain

Vertex Pharmaceuticals has partnered with world champion skier Lindsey Vonn to raise awareness of JOURNAVX (suzetrigine), its prescription non-opioid medicine for moderate-to-severe acute pain in adults. Vonn began using JOURNAVX after a serious crash in her downhill race at the 2026 Winter Games in Milano Cortina left her with multiple injuries requiring surgery; she said opioids were not agreeing with her and that the non-opioid option helped her recover, including through a painful surgical complication. JOURNAVX, approved by the FDA on January 30, 2025 as the first new class of pain medicine in over 20 years, has now been prescribed to more than one million Americans, according to the release. Vonn cited an annual U.S. acute-pain market of roughly 80 million adults prescribed medication, with about half still receiving opioids — the opioid-conversion opportunity Vertex is marketing against with this campaign.

•1mo ago

Vertex Completes Acquisition of Crinetics Pharmaceuticals and Announces Expansion of Executive Leadership Team

Vertex completed its $10.0 billion acquisition of Crinetics Pharmaceuticals, adding rare endocrine diseases as a new growth pillar. The deal includes commercialized therapy PALSONIFY and Phase 3 asset atumelnant, which have peak sales potential exceeding $5 billion and are expected to be accretive to non-GAAP operating income in 2029. Executive leadership changes include Charles Wagner expanding his COO role to oversee integration, and Jonathan Poole succeeding him as CFO effective January 1, 2027.

•2mo ago

Vertex Reports Second Quarter 2026 Financial Results

Vertex reported second quarter 2026 revenue of $3.33 billion, up 12% year-over-year, driven by continued strength in its cystic fibrosis portfolio and rapid uptake of newer products CASGEVY and JOURNAVX. The company raised its full-year 2026 revenue guidance to a range of $13.1 billion to $13.2 billion, an increase from the prior range of $12.95 billion to $13.1 billion, citing continued growth across its diversified business. Vertex also announced a definitive agreement to acquire Crinetics Pharmaceuticals for approximately $10.0 billion in cash, adding rare endocrine diseases as a fifth therapeutic pillar with the transaction expected to close in the third quarter of 2026.

•2mo ago

AbCellera Announces Collaboration with Vertex to Discover Multispecific T-Cell Engagers for Autoimmune Diseases and Other Conditions

AbCellera has entered into a collaboration with Vertex Pharmaceuticals to discover and develop multispecific T-cell engagers for autoimmune diseases and other conditions. Under the agreement, AbCellera will lead discovery and early development using its proprietary TCE platform. Vertex will fund all research and development costs and retain rights to develop and commercialize the resulting therapies. AbCellera receives $28 million in upfront payments and is eligible for future milestones and royalties. The partnership validates AbCellera's technology platform while significantly reducing its cash burn requirements for these programs. The companies may also agree to have AbCellera perform manufacturing services through Phase 1.

•3mo ago

Vertex to Acquire Crinetics Pharmaceuticals

Vertex Pharmaceuticals agreed to acquire Crinetics Pharmaceuticals for $85.00 per share in cash, representing a total equity value of approximately $10.0 billion, net of acquired cash of $8.8 billion. The deal adds Crinetics' commercial product PALSONIFY and its Phase 3 candidate atumelnant to Vertex's portfolio, with combined peak sales potential estimated at over $5 billion. Vertex expects the transaction to close in the third quarter of 2026, financing the deal with cash on hand and debt including $4.5 billion in committed bridge financing.

•3mo ago

Vertex Announces US FDA Approval for Expanded Use of CASGEVY® for the Treatment of People Ages 2 Years and Older With Sickle Cell Disease or Transfusion-Dependent Beta Thalassemia

The FDA approved expanded use of CASGEVY for patients ages 2 and older with sickle cell disease or transfusion-dependent beta thalassemia, making it the first genetic therapy approved for children this young. This expansion adds approximately 5,500 eligible children in the U.S. to the addressable market, complementing the prior approval for ages 12+. Vertex has established over 75 authorized treatment centers in the U.S. to support immediate access for newly eligible patients.

•4mo ago

Vertex Presents New Data on CASGEVY®, Including First European Presentation of Data in Children Ages 5–11, at the European Hematology Association Congress and Announces Additional Global Regulatory Submissions

Vertex presented Phase 3 data for CASGEVY in children ages 5–11 with severe sickle cell disease or transfusion-dependent beta thalassemia at the European Hematology Association Congress. In the SCD study, all 11 dosed patients were free from vaso-occlusive crises, with 100% of those with sufficient follow-up achieving the primary endpoint of being VOC-free for at least 12 months. In the TDT study, 15 patients were dosed, and 100% of those with sufficient follow-up achieved transfusion independence for at least 12 months while maintaining stable hemoglobin levels. Vertex has completed regulatory submissions in Saudi Arabia and the UK to expand CASGEVY use to younger children, with FDA review underway in the US.

•4mo ago

Vertex Presents New Data on ALYFTREK® at European Cystic Fibrosis Conference

Vertex presented positive Phase 3 data for ALYFTREK in children with cystic fibrosis ages 2 to 5, showing 65% achieved sweat chloride levels below 30 mmol/L, a marker of near-normal CFTR function. The company plans to initiate global regulatory submissions for this new indication in the first half of 2026, expanding its core franchise into younger pediatric populations. Vertex also presented long-term 96-week safety and efficacy data for ALYFTREK in older patients and Phase 3 data for TRIKAFTA in children ages 1 to <2 years, for which regulatory submissions have already begun.

•4mo ago

Vertex Announces CASGEVY® Reimbursement Agreement for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia in Germany

Vertex signed a reimbursement agreement with Germany's GKV-Spitzenverband for CASGEVY, securing sustainable access for eligible patients 12 years and older with sickle cell disease or transfusion-dependent beta thalassemia. This agreement marks the first long-term access deal for a gene therapy treating these conditions in Germany, Europe's largest healthcare market. Germany joins other countries including the UK, US, and Italy in reimbursing the CRISPR/Cas9 therapy, expanding the commercial footprint of Vertex's key growth driver.

•5mo ago

Vertex Reports First Quarter 2026 Financial Results

Vertex reported Q1 2026 revenue of $2.99 billion, up 8% year-over-year, with GAAP diluted EPS rising to $4.02 from $2.49 in the prior year. The company reiterated full-year 2026 guidance for total revenue of $12.95 billion to $13.1 billion, driven by leadership in cystic fibrosis and growth in sickle cell disease and acute pain. Pipeline progress included the completion of a rolling BLA submission for povetacicept in IgA nephropathy and the submission of CASGEVY for regulatory approval in children ages 5 to 11.

•5mo ago